Next Article in Journal
Vitamin D in Neurological Diseases: A Rationale for a Pathogenic Impact
Next Article in Special Issue
TNF-α Inhibitors Decrease Classical CD14hiCD16− Monocyte Subsets in Highly Active, Conventional Treatment Refractory Rheumatoid Arthritis and Ankylosing Spondylitis
Previous Article in Journal
Cognitive Impairment and Celiac Disease: Is Transcranial Magnetic Stimulation a Trait d’Union between Gut and Brain?
Previous Article in Special Issue
Harmful Effects and Potential Benefits of Anti-Tumor Necrosis Factor (TNF)-α on the Liver

Anti-TNF Therapy in Crohn’s Disease

Robin Phillips Fistula Research Unit, St Mark’s Hospital and Academic Institute, Harrow HA1 3UK, UK
Department of Surgery and Cancer, Imperial College, London, South Kensington Campus, London SW7 2AZ, UK
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2018, 19(8), 2244;
Received: 26 May 2018 / Revised: 4 July 2018 / Accepted: 7 July 2018 / Published: 31 July 2018
(This article belongs to the Special Issue Tumor Necrosis Factor (TNF))
Crohn’s disease (CD) accounts for a variety of clinical manifestations or phenotypes that stem from chronic inflammation in the gastrointestinal tract. Its worldwide incidence is increasing including younger or childhood-onset of disease. The natural history of Crohn’s disease is characterized by a remitting and relapsing course that progresses to complications and surgery in most patients. The goals of treatment are to achieve clinical and endoscopic remission, to avoid disease progression and minimise surgical resections. Medical treatment usually features antibiotics, corticosteroids, immunomodulators (thiopurines, methotrexate). Anti-TNF (tumour necrosis factor) therapy was approved for use in Crohn’s disease in 1998, and has changed the paradigm of treatment, leading to improved rates of response and remission in patients. There are significant considerations that need to be borne in mind, when treating patients including immunogenicity, safety profile and duration of treatment. View Full-Text
Keywords: anti-TNF; Crohn’s disease; medical treatment anti-TNF; Crohn’s disease; medical treatment
MDPI and ACS Style

Adegbola, S.O.; Sahnan, K.; Warusavitarne, J.; Hart, A.; Tozer, P. Anti-TNF Therapy in Crohn’s Disease. Int. J. Mol. Sci. 2018, 19, 2244.

AMA Style

Adegbola SO, Sahnan K, Warusavitarne J, Hart A, Tozer P. Anti-TNF Therapy in Crohn’s Disease. International Journal of Molecular Sciences. 2018; 19(8):2244.

Chicago/Turabian Style

Adegbola, Samuel O., Kapil Sahnan, Janindra Warusavitarne, Ailsa Hart, and Philip Tozer. 2018. "Anti-TNF Therapy in Crohn’s Disease" International Journal of Molecular Sciences 19, no. 8: 2244.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop